Vadastuximab disitamab vedotin antibody-drug conjugate representing a significant advancement in the approach of acute myeloid leukemia (AML). This pioneering therapy specifically targets CD33, a antigen https://opensocialfactory.com/story25749559/vadastuximab-a-deep-dive-into-cd33-specific-therapy